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ABSTRACT
Recurrent pregnancy loss (RPL) affects 2-3% of couples. Despite a detailed 
work-up, the etiology is frequently undefined, leading to non-targeted therapy. Viable 
embryos and placentae express PreImplantation Factor (PIF). Maternal circulating PIF 
regulates systemic immunity and reduces circulating natural killer cells cytotoxicity 
in RPL patients. PIF promotes singly cultured embryos’ development while anti-PIF 
antibody abrogates it. RPL serum induced embryo toxicity is negated by PIF. We 
report that PIF rescues delayed embryo development caused by <3 kDa RPL serum 
fraction likely by reducing reactive oxygen species (ROS). We reveal that protein 
disulfide isomerase/thioredoxin (PDI/TRX) is a prime PIF target in the embryo, 
rendering it an important ROS scavenger. The 16F16-PDI/TRX inhibitor drastically 
reduced blastocyst development while exogenous PIF increased >2 fold the number 
of embryos reaching the blastocyst stage. Mechanistically, PDI-inhibitor preferentially 
binds covalently to oxidized PDI over its reduced form where PIF avidly binds. PIF 
by targeting PDI/TRX at a distinct site limits the inhibitor’s pro-oxidative effects. 
The >3kDa RPL serum increased embryo demise by three-fold, an effect negated by 
PIF. However, embryo toxicity was not associated with the presence of putative anti-
PIF antibodies. Collectively, PIF protects cultured embryos both against ROS, and 
higher molecular weight toxins. Using PIF for optimizing in vitro fertilization embryos 
development and reducing RPL is warranted.
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INTRODUCTION
In order to effectively develop in culture, embryos 
depend on autocrine factors [1, 2]. Embryos are also highly 
vulnerable to reactive oxygen species (ROS) and multiple 
attempts have been utilized to reduce such vulnerability 
[3, 4]. Identification of an endogenous compound that 
would bind specific targets within the embryo to reduce 
ROS or other toxicity could be of great benefit. There are 
ongoing concerns that culturing multiple embryos for a 
prolonged period can lead to epigenetic adverse effects 
[5-8]. Cases in point are rare imprinting disorders such 
as Angelman syndrome, Beckwith-Wiedemann syndrome 
and retinoblastoma in children who are conceived with the 
use of in vitro fertilization (IVF) [9]. Prolonged embryo 
cultures can also lead to premature delivery [10].
Embryos that remain viable throughout gestation 
secrete an endogenous compound that promotes self-
development and protects against adverse environment. 
PreImplantation Factor (PIF) is a CD2 associated protein 
product present in embryos, fetal and placental tissues 
and in maternal circulation of several mammals [11-16]. 
In embryo culture media PIF is detectable at the 2-cells 
stage in mouse, 4-cells stage in humans and by 6-cells 
in bovine embryos [16, 17]. PIF levels in pregnant 
circulation just ten days after artificial insemination 
correlate with live birth [18]. Exogenous administration 
of synthetic PIF (matches native peptide sequence) targets 
viable bovine, equine and murine embryos in autocrine 
and paracrine manner. The effect is not replicated by a 
control, scrambled PIF [16, 17]. 
In singly cultured IVF bovine embryos, short-
term exogenous PIF promotes blastocyst development 
[19], while anti-PIF monoclonal antibody has inhibitory 
effects [16]. PIF promotes endometrial receptivity 
independent of progesterone and trophoblast invasion 
[15, 20-23]. To establish embryo/maternal dialogue, PIF 
binds systemic CD14+ cells (monocytes) and mitogen-
activated lymphocytes, reducing proliferation and leading 
to TH2/TH1 cytokine bias. Interaction with CD3+ T 
cells increases in maternal circulation during pregnancy, 
reflecting adaptive response [24, 25]. In non-pregnant 
pre-clinical models of autoimmunity, transplantation and 
brain injury, PIF reduced oxidative stress and protein 
misfolding via an integrated local and systemic effect [22, 
23, 25-33]. This observation led to the FAST-Track FDA-
clinical trial using PIF to treat an autoimmune disease 
recently completed successfully demonstrating high safety 
(NCT02239562). 
With respect to recurrent pregnancy loss (RPL), 
PIF reduced circulating NK cells toxicity by decreasing 
pro-inflammatory CD69 expression [34]. The embryo 
toxicity assay (ETA) is used clinically to examine RPL 
serum toxicity, which PIF negates, promoting both 
development and reducing embryo demise in vitro [35, 
36]. There is also evidence that certain autoantibodies 
impair cultured embryo development [36, 37]. PIF’s 
direct protective effects in the embryo and immune cells 
involve prime targets such as protein-disulfide isomerase 
(PDI) containing the antioxidant thioredoxin (TRX) 
domain and heat shock proteins (HSP70 and HSP90) [17] 
[38]. Both proteins reduce oxidative stress and protein 
misfolding essential for embryo development [39]. PDI/
TRX is involved in oocyte maturation, [40] gamete fusion 
[41] zona hardening and monospermy [42] as well as 
proliferation preventing inner cell mass apoptosis [43]. 
Also, addition of exogenous TRX protects against ROS 
[7]. However, whether PIF by targeting endogenous PDI/
TRX in the embryo can protect against ROS is unknown, 
though plausible, since PIF protects against ionized 
radiation [44]. 
RPL serum is complex, impairing both embryo 
development and survival [19]. Herein, we examine 
whether PIF can counteract those distinct phenomena 
which may be due to ROS. On the other hand, PIF’s 
autotrophic effects on the embryo are negated by added 
anti-PIF antibody [16]. Moreover, PIF anti-apoptotic 
action is dependent on the p53 pathways and expression 
in the placenta is low in intrauterine growth restriction 
(IUGR) and preeclampsia which may be caused by 
putative anti-PIF antibodies [45]. Therefore, we examined 
whether such putative antibodies are present in the RPL 
sera. We report that PIF protects against ROS supporting 
its supplementation to protect against epigenetic changes 
that may occur in long term IVF cultures.
RESULTS
PIF acts as a rescue factor, negating embryo 
toxicity induced by fractioned RPL serum
We previously showed that PIF protects against 
embryo toxicity by negating the 5% unfractionated 
RPL sera. [19] To better define toxic factors involved 
and mechanisms involved in PIF induced protection 
we therefore separated patients’ with embryo toxic 
serum (ETS+) to low < 3kDa and higher > 3kDa 
molecular weight fractions to ascertain whether embryo 
development was affected differentially. The preliminary 
with fractionated sera showed that PIF at 0.312µg/ml 
was most effective in preventing embryo toxicity, and 
used for testing. The premise was that ROS are low 
molecular weight species < 3kDa and highly toxic to the 
embryo. Since PIF protects against oxidative stress, such 
a separation may capture those toxins effectively. The < 
3kDa fraction added to different mouse embryo cultures 
led to a significant delay in embryo development where 
only half of the embryos reached to the blastocyst stage. 
However, by adding PIF to the embryo cultures, up to 
two fold increase in the blastocyst rate was observed, 
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composite data (85.3% vs 44.1%, (Df, 10.8, p < 0.009) 
(Figure 1A). Importantly, no differences were noted in 
embryo demise rates.
When the > 3kDa fraction was added to embryo 
cultures the high rate of embryo demise was reversed by 
the addition of PIF, composite data (15.2% vs 45.5% in 
control, Df 7.1, p < 0.007) (Figure 1B) (Supplementary 
Table 1) Moreover, the number of embryos reaching the 
blastocyst stage in the PIF treated embryos was slightly 
higher, 48.5% in PIF treated as compared to control, 36.4% 
(Df, 5.6, p < 0.01). There were also major differences 
between PIF’s effect in < 3kDa fraction reaching high 
blastocyst rate, 85.3%, as compared with PIF’s effect in 
the > 3kDa fraction reaching only 48.5%. This reveals 
PIF’s major protective effect mostly on embryo demise. 
PIF embryo-protective action against ETS+ does 
not involve neutralization of anti-PIF antibodies
The > 3KDa fraction of the ETS+ RPL serum 
mostly increased embryo demise which PIF negated. Such 
toxicity may involve circulating antibodies [36] including 
anti-PIF antibodies which inhibited embryo development 
[19]. Considering that PIF expression is low in high risk 
pregnancy placentae [23], herein we examined whether 
this may be related to endogenous anti-PIF antibodies. 
The embryo-toxicity assay was determined in 28 patients 
with a history of RPL, determining those with embryo 
toxic ETS+ or (ETS) sera, control group, [19]. The 
presence of anti-PIF antibodies were tested in both groups 
by using a newly developed direct ELISA. To examine 
anti-PIF-antibody presence each sample was tested in 
ovalbumin -PIF conjugate, PIF alone or ovalbumin alone 
coated on the plate were compared to control. As Figure 
2A (ETS+ patients) and 2B (ETS- patients) show, in all 
cases irrespective of ETS status, the PIF coated alone 
plate had non-detectable anti-PIF-antibody levels in 
the RPL sera (Supplementary Figures 1-3, assay plate 
images). In contrast, the ovalbumin alone coated plates 
showed significant antibody presence likely against egg 
components. The combined PIF-albumin coated plate 
did not further potentiate the optical density (OD) as 
compared with ovalbumin coated alone. However further 
analysis using a stringent 0.6 OD as cut off showed that 
higher ETS+ patients 11/14 had anti-Ova antibody vs ETS- 
patients who had only in 4/14 cases (Df 7.0, p < 0.007). 
PIF’s effect on protein-disulfide isomerase (PDI) 
inhibitor induced ROS in embryo cultures
The above data showed that the < 3kDa fraction 
induced delay in embryo development was negated by 
PIF, while not affecting embryo survival. Whether the 
stunted embryo development is due to ROS was further 
examined. This is due to the fact that PIF’s prime targets 
in the embryo are PDI/TRX proteins which are known to 
reduce oxidative stress [17, 19]. The effect of a covalent 
PDI inhibitor was examined in bovine embryos cultured 
in groups (Figure 3A) (Supplementary Table 2). The PDI 
inhibitor 16F16 added alone reduced the cleavage rate 
as compared to the control group, media culture only (p 
= 0.005), but was not different from the other groups. 
Addition of the PDI inhibitor reduced the number of 
embryos developing to the blastocyst stage, whether 
as a proportion of the total number of oocytes or as a 
proportion of cleaved zygotes (p < 0.0001). Logistic 
regression indicated that the interaction of 16F16 and PIF 
was significant (p = 0.02). Further analysis confirmed that 
this was because PIF alone had no significant effect (p = 
0.85), but the detrimental effect of 16F16 was partially 
reversed by inclusion of PIF in the culture medium. 
Blastocyst rate was significantly different for 16F16 
versus 16F16 plus PIF (p = 0.0056 considering total 
oocytes included and p = 0.0092 considering only cleaved 
Figure 1: PIF effect on fractionated RPL sera cultured with embryos. ETS+ serum was fractionated by Amicon filter to < 3 and 
> 3 kDa fractions. The effect of these fractions was tested in standard embryo toxicity assay determining the effect of PIF (0.31µg/ml). A. 
In the < 3 kDA fraction, PIF increased the rate of embryos reaching the blastocyst stage. *(Df, 10.8, p < 0.009) B. In > 3 kDA fraction, PIF 
decreased the rate of embryos that became atretic. *(Df 7.1, p < 0.007). See Supplementary Table 1  for further information. 
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Figure 2: Analysis of anti-PIF antibody presence in RPL serum. Twenty eight patients categorized by the ETS assay as ETS+ or 
ETS- N = 14/group were tested for presence of anti-PIF antibodies. (see methods for assay details). A. Anti-PIF Ab in ETA positive Patients, 
B. Anti-PIF Ab in ETA negative Patients. The data showing the lack of anti-PIF antibody in both patient’s groups. The presence ova albumin 
in the assay leads to non-specific binding, but not observed when PIF tested alone. See Table 2 for statistical evaluation.
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zygotes). The total blastocyst formation in control was 
40% which was reduced four-fold by the PDI inhibitor. 
Importantly PIF increased this rate over two fold. PIF 
supplementation alone did not change the rate of embryo 
development to blastocyst stage relative to the control 
group (p = 0.82). 
PIF reduces ROS by avidly targeting reduced PDI 
at a site distinct from the covalent PDI inhibitor- 
in silico design
The increase in ROS by the PDI/TRX inhibitor 
delayed embryo development which PIF reduced, similar 
Figure 3: PIF effect on PDI inhibitor induced oxidative stress in cultured embryos. Bovine IVF embryos were cultured in the 
presence of covalent PDI inhibitor. The effect of PIF at ~1:1 ratio was determined after 8 days of culture. PIF increased the number embryos 
that reached the blastocyst stage both as a percent of the total as well the percent of the cleaved embryos. *(p < 0.05). See Supplementary 
Table 2 for further information. B., C. PIF and PDI inhibitor (16F16) interaction with PDI. PIF binds more avidly to reduced PDI, forming 
higher number of interactions to His, but also highest electrostatic potential based interaction energies compared to 16F16. B. Comparative 
docking of PIF and 16F16 to PDI structural models of oxidized PDI. C. Same docking to reduced form of PDI. PIF binding was predicted 
using flexible peptide docking algorithm FlexPepDock, while small molecule inhibitor 16F16 binding was predicted using AutoDock Vina 
semi-rigid docking. Histidine residues are depicted in blue, PIF is depicted in red, 16F16 conformers are depicted in different colors. 
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to the < 3kDa fractionated serum. Possible protective 
mechanisms involved in PIF’s action [17] are exerted by 
docking with a higher energy to oxidized PDI. Using a 
frequently employed small molecule docking algorithm 
of Vina, several docking places of the small molecule 
inhibitor of PDI, 16F16 were found when docking models 
of PIF and 16F16 were compared for oxidized (Figure 3B) 
and reduced forms (Figure 3C) of PDI. Crystallography 
models of human PDI indicated that PIF binds closely to 
one of the most frequently predicted (based on number of 
models) sites of 16F16 in reduced PDI. 
PIF was found (by FlexPepDock) to be bound at the 
same site as the top scored Vina docking predicted 16F16 
model. Most of the other models indicated binding at the 
same place (Figure 3C).
Using LigPlot+ [46] donor-acceptor and 
hydrophobic interactions were depicted in the binding 
interfaces of oxidized and reduced forms of PDI when 
bound by either PIF or 16F16. A higher number of 
hydrophobic interactions in favor of the reduced PDI was 
found when bound to PIF (Figure 4B), compared to the 
oxidized form of PDI (Figure 4A). Only one His (His412) 
participated in the PIF binding interface of the PIF-oxiPDI 
complex, while two His (His390, His429) were engaged in 
PIF-redPDI complex. 
The specific PDI small-molecule inhibitor 16F16 
was found to act as a thiol alkylating agent, where a highly 
electrophilic moiety forms a covalent bond with the PDI 
active site to prevent further reductase activity [47]. Since 
16F16 inhibitory activity against PDI is driven not by 
Figure 4: Analysis of PIF and PDI inhibitor interaction with PDI. A. Schematic diagram of oxidized PDI-PIF interactions 
generated by LigPlot+. B. Schematic diagram of reduced PDI-PIF interactions generated by LigPlot+. C. Schematic diagram of oxidized 
PDI-16F16 interactions generated by LigPlot+. D. Schematic diagram of reduced PDI-PIF interactions generated by LigPlot+. Hydrogen 
bonds are indicated by dashed lines between the atoms involved, while hydrophobic contacts are represented by an arc with spokes 
radiating towards the ligand atoms they contact. The contacted ligand atoms are shown with spokes radiating back.
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binding affinity but by the redox potential of their reactive 
moieties [48], we focused on the role of the PDI active 
site. PDI is but one member of a large superfamily of 
thioredoxin proteins that mediate the reduction, oxidation 
and isomerization of disulfide bonds on other proteins [49, 
50]. The N-terminal active site cysteine of the domain 
of PDI participating in disulfide bond isomerization 
is stabilized as a thiolate anion by the pKa of the local 
histidine imidazole [51].
Since 16F16 was found to bind His residues in 
some of its known targets [48] we followed His pattern of 
binding towards PDI as well. It (F16F) was bound to only 
one His in both oxiPDI (His373) and redPDI (His429), 
but other close by residues that were bound by 16F16 in 
oxiPDI-16F16 complex like Ser413, Phe414, were also 
bound by PIF (Figure 4C). Interestingly, only Phe297 was 
shared by 16F16 and PIF in redPDI complex (Figure 4D).
Binding similarities of PIF and 16F16 to PDI
To explain the similarity in reduced PDI binding 
pockets of PIF and 16F16, some binding/interaction/
solvation energies of 16F16/PIF and oxi/red PDI 
(Supplementary Table 3) were estimated.
PIF had the highest electrostatic potential based 
interaction energies (APBS binding E, Electrostatic E, 
Electrostatic Interaction, MEP interaction E) to redPDI, 
superseding 16F16. This resulted in increased solvation 
energy of PIF as well in reduced form of PDI when 
compared to its oxidized form. PIF, compared to 16F16 
in its docking to redPDI, demonstrates better energetic 
binding properties. This corroborated the LigPlot+ scheme 
of pocket binding where 16F16 was found to have several 
ligand bonds of non-polar and hydrophobic interactions, 
Figure 5: PIF mechanism of action on PDI oxi/reduction pathways. Small molecular inhibitor 16F16 and PIF act differently on 
oxidative protein folding exerted by PDI. The scheme is adopted by “Biochemical Basis of Oxidative Protein Folding in the Endoplasmic 
Reticulum” by Benjamin P. Tu et al. [66]. Protein disulfide isomerase (PDI), has two thioredoxin-like active sites, which both contain two 
cysteine residues and it is responsible for the formation of the disulfide bonds in unfolded eukaryotic proteins. By transferring the disulfide 
bond between these two cysteine residues onto the folding protein it is responsible for the folding protein oxidation, becoming reduced 
one (rPDI). Then PDI must be reoxidized so it can further catalyze the formation of disulphide bonds in unfolded proteins. This is carried 
out by an endoplasmic reticulum (ER) membrane-associated protein, Ero1p, which forms a mixed disulfide with PDI, which is resolved 
by a nucleophilic attack of the second cysteine residue in one of the active sites of PDI. As a result, oxidized PDI (oPDI) is obtained. 
Ero1p itself is oxidized by transferring electrons to molecular oxygen. As it is an FAD-binding protein, this transfer of electrons is strongly 
favored when Ero1p is bound to FAD. In misfolded proteins, incorrect disulfide bonds are rearranged by reduction, which is carried out by 
oxidation of reduced glutathione (GSH) to oxidized glutathione (GSSG). 16F16 and PIF predominant binding mode of action shown. ER, 
endoplasmic reticulum; PDI, Protein disulfide isomerase; rPDI, reduced PDI; oPDI, oxidized PDI.
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while PIF had more hydrophobic interactions and two 
hydrogen bonds. In contrast, in oxiPDI complex 16F16 
had the same number hydrogen bonds as PIF. 
Based on MEP interaction energy and Electrostatic 
energy profiles of binding, we conclude that 16F16 binds 
more avidly to oxiPDI than to redPDI, and that PIF is even 
more strongly bound to redPDI than 16F16 is. This could 
explain its ability to at least partially abrogate 16F16 effect 
at a roughly one to one molar ratio of PIF and inhibitor. 
Thus, PIF, through targeting at a distinct site, has the 
ability to minimize the PDI inhibitor action.
PIF interference with 16F16 small molecule 
inhibitor is considered in the context of PDI oxidative 
folding, suggesting that different modes of action of PIF 
and 16F16 allow for the observed phenomenon (Figure 5). 
PIF’s stronger binding with reduced PDI abolished 16F16 
action on oxidized PDI, hence PDI re-oxidation was re-
established. 
DISCUSSION
The major finding herein is that ROS likely 
present in < 3kDa RPL serum delays cultured embryos 
development which PIF prevents. Mechanistically, 
pro-oxidative PDI covalent inhibitor induced delay is 
reduced by PIF, further substantiating such premise. PIF 
targets PDI/TRX in the embryo when the enzyme is in 
its reduced form and binds at a distinct site, impairing 
covalent PDI inhibitor binding leading to ROS formation. 
In the > 3kDa RPL sera fraction, PIF reduced embryo 
demise and increased blastocyst rate, which is not exerted 
through neutralization of anti-PIF antibodies. Thus the low 
expression of PIF in the placenta in high risk pregnancy 
is not due to the presence of circulating putative anti-PIF 
antibodies. [45] 
Currently the serum for embryo toxicity is analyzed 
as a whole, without separation [52-55]. Herein we show 
for the first time major differences between low and 
higher molecular weight ETS+ effects and associated PIF-
induced protection. In the < 3kDa fraction PIF prevented 
a delay in development possibly due to ROS. Singly 
cultured bovine embryos secrete and are targeted by PIF, 
to promote development confirmed herein [16, 17, 19]. 
The covalent PDI inhibitor binds PDI/TRX —a prime PIF 
target— severely impairs embryo development [17]. Mild 
effect in cleavage was coupled with four-fold decrease in 
blastocyst rates, substantiating the PDI/TRX critical role. 
[17]. PDI inhibitor (16F16) at > 3.125uM dose led to total 
arrest of embryo development, while other cells were 
impaired at different concentrations [44]. Another PDI 
inhibitor, bacitracin, already damaged oocyte maturation at 
5 µM concentration [35]. Thioredoxin added to pronuclear 
stage embryos released 2 cell block and promoted embryos 
development [7, 56]. PIF targeted the endogenous PDI/
TRX suggesting an autotrophic loop, supporting its 
critical role [16]. Beyond targeting PDI/TRX, by binding 
HSPs and Kv1.3b K+ channel, PIF may further amplify 
the protective activity [17, 32]. Collectively, both the < 3 
kDa ETS+ fraction and the PDI inhibitor delayed embryo 
development likely exerted through ROS formation which 
PIF fully in the former and partially in the latter reversed. 
This is critical for IVF success. 
PIF as single administration more than doubled the 
blastocyst rate despite the low molar PIF to PDI inhibitor 
~1:1 ratio and the enriched specific SOF-BE1 media 
containing Myoinositol (an antioxidant), and insulin [57]. 
Insulin may interfere with PIF activity since the peptide 
targets the insulin degrading enzyme in the embryo [17]. 
Failing embryos may release lysosomes and peptidases, 
likely to degrade PIF in long term culture [18]. SOF-BE1 
media is optimal, therefore lack of PIF effect was expected 
in contrast to that observed in singly cultured embryos 
[35]. 
The PDIs are enzymes that share similar functions 
mostly acting through thioredoxin. PDI/TRX interacts 
with HSPs, ubiquitin, serpins and importantly CD9, 
involved in sperm/egg interaction which may also be 
impaired indirectly following exposure to 16F16 (String 
analysis). PDI mechanism is expected to be complex 
and the depiction is representative (Figure 5). In order 
to function, the endogenous enzyme needs to be re-
oxidized to enable protein folding. The reduced (dithiol) 
form of PDI is able to catalyze a reduction of mis-paired 
thiol residues of a particular substrate, also acting as an 
isomerase. oxiPDI is more likely to bind to 16F16. 
During the folding process, PDI becomes reduced, 
obtaining electrons from the protein SH-groups, thus 
creating a disulfide bond. In order to get re-oxidized, PDI 
has to donate its electrons to Ero1p, which in turn binds 
to FAD protein. Unlike bacteria, where this is coupled 
to the respiratory chain, in eukaryotic cells the electrons 
are transferred to molecular oxygen, possibly causing 
excessive ROS. Human hPDI, (abb’xa’) is in both reduced 
and oxidized states, and has four thioredoxin domains, 
arranged in a horseshoe shape with two CGHC active sites. 
In reduced hPDI, domains a, b, and b’ line up in the same 
plane, whereas domain a’ twists ~45° out. In oxidized 
hPDI, the four domains are organized differently to stay 
in the same plane, and the distance between the active 
sites increases. In contrast to the closed conformation of 
reduced hPDI, oxidized hPDI exists in an open state, with 
more exposed hydrophobic areas and a larger cleft with 
potential for substrate binding [58]. Sterically, PIF could 
have less effect on oxiPDI; this form of PDI is involved 
in protein folding but not in electron exchange. Hence, 
the redPDI is less likely to produce ROS. In the absence 
of PIF, 16F16 would likely bind to both PDI forms and 
impair both accepting and donating electrons. Thus, 16F16 
binding predominantly to oxiPDI could cause excessive 
ROS and lead to embryo damage. [59,60] PIF, on the other 
hand, is able to block redPDI, most likely by impairing 
16F16 binding. This prevents redPDI from transitioning 
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to oxiPDI, a step where excessive electrons, ROS, are 
produced. At higher PIF (5-10 fold) concentration, the 
binding to PDI could drive the inhibitor out from its 
pocket, thus rendering PDI in a favorable, reduced state. 
Such data support the view that PIF action is target-
specific. 
Interestingly, the > 3kDa RPL serum three-fold 
increase in embryo demise and mildly reduced embryo 
development was negated by PIF. Thus, in RPL PIF can 
negate disparate toxic elements and NK cells cytotoxicity 
supporting therapeutic potential [34]. RPL serum contains 
several embryo-toxic compounds and antibodies [36, 
61]. Consequently, they are used in patients’ workup 
and possibly as targets for therapy. We show that PIF-
induced protective action on the embryo does not involve 
neutralization of putative anti-PIF antibodies examined 
in both ETS+ and ETS- samples. The anti-ovalbumin 
antibody concentration varied significantly from non-
detectable to high levels irrespective of whether it 
was from ETS+ or ETS- samples, indicating a lack of 
involvement in the embryo toxic activity. Thus planned 
therapeutic application of PIF in RPL and for high risk 
pregnancy treatment is unlikely to be negated by the 
presence of those antibodies. 
Overall, PIF, a human embryo derived compound, 
made as synthetic PIF GMP quality, may be used to 
supplement IVF culture media to prevent potential embryo 
toxicity that develops in prolonged and multiple embryo 
cultures. 
Using fractionated sera is a new approach, enabling 
to identify toxic effects which can translate to adverse 
pregnancy events post-implantation. Further fractionation 
could reveal rapidly and non-invasively critical elements 
involved in embryo wellbeing and may support 
appropriate intervention starting prior to pregnancy. 
In conclusion, PIF promotes both embryo 
development and survival by negating ETS+ effect. 
PIF’s protective effect is dependent on targeting PDI by 
reducing ROS of cultured embryos. Both murine and 
bovine embryos were protected by PIF which supports 
its clinical application also to human IVF. PIF completed 
successfully phase I clinical trial for autoimmune disease 
(NCT02239562). The results herein support PIF’s 
translation for targeted RPL therapy as well. 
MATERIALS AND METHODS
Synthetic preImplantation factor (PIF) and PDI 
inhibitor
PIF (MVRIKPGSANKPSDD) was 
synthesized by solid phase peptide synthesis (Peptide 
Synthesizer, Applied Biosystems) employing Fmoc 
(9-flourenylmethoxycarbonyl) chemistry at Bio-Synthesis 
(Lewisville, TX). Final purification was carried out by 
reversed-phase HPLC and identity was verified by matrix-
assisted laser desorption/ionization time-of-flight mass 
spectrometry and amino acid analysis at > 95 % purity. 
16F16, a covalent PDI inhibitor, was purchased from 
Sigma Aldrich (St. Louis, MO).
PIF effect on mouse embryos cultured with 
fractionated embryo-toxic serum (ETS+)
The study was approved by the CARI Research 
Institute, Chicago, IL. Archived frozen serum samples 
from patients with recurrent pregnancy loss of various 
etiologies were studied. Serum samples which were 
previously found to be toxic for cultured mouse 
embryos (ETS+) determined by using established 
criteria as previously reported [19, 36] was chosen. 
PIF promotes cultured blastocysts development, and in 
RPL unfractionated sera, PIF both prevented a delay in 
development and reduced embryo demise [19]. The effect 
is also specific since scrambled PIF (same sequence but 
in a random order, used as a control) was not up-taken by 
cultured mice embryos [16]. Our previous report showed 
that under optimal conditions the rate of mouse embryos 
reaching the blastocyst stage is above 80% [19]. 
Embryo Toxicity Assay was performed as 
previously reported. [19] These sera were used for the 
anti-PIF antibody (see below) as well for the serum 
fractionation. Briefly, two-cell stage embryos (N = 134) 
were collected from super ovulated mated CB6F1/J mice. 
Removed oviducts were dissected under microscope and 
embryos collected were transferred into mHTF media 
(Cat# 2001, InVitroCare, Frederick, MD). To better 
understand the etiology of embryotoxicity the serum 
samples were separated into low and high molecular 
weight fractions using a filter system. Serum filtration 
was performed using a < 3 kDa Amicon Ultra-4 system 
following manufacturer’s protocol. Collected tubes 
were spun at 4000 x g for 20min using 3kDa filter. The 
resulting < 3kDa filtrate and > 3kDa serum proteins 
were collected. The separated < 3kDa and > 3kDa serum 
fractions at 5% were added to randomly partitioned 2-cell 
mouse embryos with or without (48-6250 ng/ml) PIF as 
a screening experiments. Based on the preliminary data 
generated the 0.312 µg/ml PIF concentration was chosen 
as most effective and was tested at least 5 embryos (per 
experiment, patient < 3 kDa and > 3kDa groups). The 
culture media added 5% fractionated sera were adjusted 
to a total to 500µl culture volume with BSA [19]. 
Embryos were cultured in Nunc Petri dish in 500µl of 
culture medium HTF HEPES (cat# 2001, InVitroCare, 
Frederick, MD) in the presence of 5% heat inactivated 
patients’ < 3kDa or > 3kDa sera under mineral oil by 
incubating at 37°C with 5% CO
2
 for 3 days maintaining 
pH 7.2 throughout the experiment as previously shown 
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[19]. At the end of the culture period at 72 hours, embryos 
developmental stages were recorded using established 
morphological criteria by using a microscope. Embryos 
were categorized as blastocysts, pre-blastocysts, morula, 
number of cells, 6-8, 2-4 or atretic embryos, and evaluated 
by two different observers (CWS, RGR). 
ELISA to detect anti-PIF antibody in human 
serum
Anti-PIF antibody detection was carried out in 
28 patients with a history of RPL having archived sera 
known to be ETS+ or ETS- based embryo toxicity 
assay. For such identification an indirect enzyme-linked 
immunosorbent assay for qualitative determination of 
anti-PIF antibody was developed. The 10X Ultracoat II, 
coating buffer (Leinco Technologies, USA) was diluted to 
1X with water just before use, and used to dilute dextran-
PIF or ovalbumin-PIF or ovalbumin alone to 100ng/ml 
final concentration and dispensed 100µl per well Nunc 
Maxisorp plate. Subsequently, the plate was sealed and 
incubated at 40C overnight. Following incubation, the 
coating solution was discarded and washed with PBST, 
4 times in a plate washer. 300µl of SEA BLOCK, (Fisher 
Scientific, Cat. No.0037527) blocking buffer was added to 
each well and incubated for one hour at 37C. Subsequently 
the plate was washed with PBST for 4 times and dried. 
The serum samples were diluted to 1:100 with PBST (1 
part sera: 99 part PBST) running the samples in triplicate. 
The 100 µl of the diluted serum samples were added 
to the pre-coated plates coated with PIF or ovalbumin-PIF 
or ovalbumin alone and incubated at 37Cfor one hour. 
After plates were washed 4 times using PBST (0.1% 
Tween 20) and dried. Goat α-human IgG conjugated to 
alkaline phosphatase, (Roche, Product No. 03-118-495-
001) in1% Fish skin gelatin (FSG) in PBS was diluted to 
1:2000 of this 100 µl of conjugate was added to the plate 
and incubated at 370C for 30 minutes. Subsequently, the 
plate was washed and 100µl of pNPP substrate was added, 
incubated for 10 minutes in dark, at room temperature. 
Reaction was stopped by adding NaOH and the plate was 
read at 405 nm. The diluted anti-PIF monoclonal antibody 
was used as a positive control, when using the appropriate 
secondary antibody. In addition, a secondary antibody 
control and blank control were used. As control for PIF 
coat, anti-PIF antibody conjugated to biotin was added to 
six wells and detected by adding ultravidin HRP. TMB 
substrate was added to all six wells, but stop solution was 
added only to three wells, so as to differentiate blue (no 
stop) and yellow (stopped). The intensity of the signal 
is directly proportional to the concentration of anti-PIF 
antibody in the sample.
In vitro production of bovine embryo
Bovine ovaries were obtained immediately after 
slaughter and transported in warmed (37°C) sterile saline 
inside insulated containers to the laboratory at Cornell 
University as previously described [17]. Briefly, the 
ovaries were rinsed in warmed sterile saline solution 
in the laboratory and then allowed to cool gradually to 
approximately 25 °C by the end of the oocyte retrieval 
procedure. All visible follicles between 2 and 8 mm in 
diameter were aspirated with 18g hypodermic needles 
using a vacuum pump set so that 22.5-25 mL of fluid was 
aspirated per minute. Follicular fluid was aspirated into 
50 mL conical tubes up to 25 mL per tube. The tubes were 
allowed to stand for at least 15 min before the sedimented 
“pellet” was carefully removed and transferred to a 10 
cm Petri dish containing holding medium. Cumulus-
oocyte complexes (COCs) were then sorted and selected 
based on visual appearance; only those with homogenous 
cytoplasm, non-expanded cumulus, and with at least 
3 layers of cumulus cells surrounding the oocyte were 
selected for transfer to the maturation medium. Once 
identified and removed, the COCs were washed in holding 
medium and transferred into maturation medium.
Recovered COCs were matured in groups of 10-
30 for 24 hrs in TCM-199 (with Earle’s Salts) enriched 
with 10 % FCS, 0.2 mM sodium pyruvate, 1 mM alanyl-
glutamine, 0.1 mM taurine, 0.1 mM cysteamine, 1 µg/ml 
estradiol, 85 mU/ml bovine follicle stimulating hormone 
(FSH, SIOUX Biochemical, Inc., Sioux Center, IA), 
0.1 µg/ml gentamicin, and 10 ng/ml epidermal growth 
factor (EGF) at pH 7.35 ± 0.02 and osmolarity of 300 ± 2 
mOsm and covered with light mineral oil in a humidified 
atmosphere at 38.5°C with 5 % CO
2
 in air. Matured 
oocytes were transferred to a modified IVF medium 
(Fert-TALP; [61]) supplemented with 0.5 mM fructose, 
0.2 mM non-essential amino acids, 6 mg/ml BSAFFA 
Fraction V, 30 µM penicilamine, 15 µM hypotaurine, 
1.5 µM epinephrine (PHE), 22 µg/ml heparin, 20 µg/ml 
gentamicin, covered with light mineral oil in a humidified 
atmosphere at 38.5°C with 5 % CO
2
 in air for 18 h (pH 
of 7.38 ± 0.01, 285 ± 1 mOsm). The IVF procedure for 
bovine species was recently reported. [16, 19] Frozen 
semen straws from the same two bulls were combined for 
each experiment. The straws were each thawed at 37°C 
for 2 min and then combined prior to centrifugation. 
Sperm were selected by double density gradient (90% 
and 45% BoviPure®; Nidakon, Sweden, distributed by 
Spectrum Technologies, Healdsburg CA) centrifugation 
at 400x g for 20 min in centrifuge buckets warmed to 
37°C. Subsequently, sperm were washed in 5 ml of 
BoviWash (Nidakon, Sweden, distributed by Spectrum 
Technologies, Healdsburg CA) at 400 x g for 5 min and 
added to oocytes in fertilization medium (SOF-FERT) at a 
final concentration of 1.5 x 106 sperm/ml and cultured for 
18 hrs at 38.5 °C with 5 % CO
2
 in air.
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After vortexing to remove cumulus cells, 
presumptive zygotes were transferred in groups of 25 to 
50 per wells of a 4-well plate each containing 400 µL of 
medium (appropriate for each group) overlaid with 300µL 
of mineral oil and preconditioned by 24 hrs exposure to 
incubator conditions (38.5°C, humidified atmosphere of 5 
% CO
2
, 7 % O
2
 in Nitrogen) [62]. The medium used was 
“synthetic oviduct fluid - bovine embryo 1” (SOF-BE1) 
[63,64].
Effect of PDI inhibitor (16F16) and PIF on 
cultured embryos
Short term exposure of PIF to singly cultured bovine 
embryos post-fertilization promoted their development up 
to the blastocyst stage after exposure for only three days 
followed by four days of observation. [19] To determine 
the effect of PIF on cultured embryos development where 
herein cultured in large groups alone and in the presence 
of the PDI inhibitor, four experimental groups were 
examined: control (SOF-BE1 medium), PIF supplemented 
(5µM) medium, 16F16 (a PDI inhibitor) supplemented 
(3.125µM) in medium, and the combination of 16F16 
and PIF at these concentrations. Experimental conditions 
were applied after fertilization and cumulus cell removal. 
Preliminary experiments were conducted to identify a 
concentration of PDI inhibitor that would only partially 
inhibit embryo development. Eventually, a concentration 
of 3.125 µM was used. All higher concentrations ( > 
3.125µM) completely inhibited embryo development (data 
not shown).
PDI binding by PIF and 16F16 - an in silico 
docking analysis to establish binding site and 
potential mechanism of action
Modeling in silico of PIF docking to PDI
PIF docking to PDI was examined following the 
in silico flow as previously described [17, 25]. Briefly, a 
PIF model was generated using de novo peptide structure 
prediction, based on the primary structure (amino-acid 
sequence) alone [46,47] The top scored models generated 
by the server PEP-FOLD (http://bioserv.rpbs.univ-paris-
diderot.fr/PEP-FOLD/) were used further in docking 
simulations. The potential binding of PIF to PDI surfaces 
was assessed in terms of probability, PIF participating 
residues, targeted protein ligand-receptor surface 
determining residues by using the PepSite 2 server (http://
pepsite2.russelllab.org/). High-resolution peptide docking 
of PIF to the oxidized and reduced forms of PDI (obtained 
as PDBs 4EL1 and 4EKZ) was done using Rosetta 
FlexPepDock server (http://flexpepdock.furmanlab.
cs.huji.ac.il/). A PDB encoded model of the de novo PIF 
model was supplied in close proximity and its location 
was specified by the PepSite 2. FlexPepDock allows 
full flexibility to the peptide and side-chain flexibility 
to the target protein, thus providing accurate refinement 
of the peptide structure, starting from up to 5.5 RMSD 
of the native conformation. (RMSD - root-mean-square 
deviation, is the measure of the average distance between 
the atoms [usually the backbone atoms] of superimposed 
proteins) [47]. The PIF binding scores to models obtained 
by crystallography of the reduced and oxidized forms of 
PDI were previously estimated and published in Barnea 
et al [17]. 
Modeling in silico of PDI inhibitor small molecule 
16F16 binding to PDI
16F16 molecular structure (obtained as SDF file) 
and oxidized and reduced forms of PDI (obtained as 
PDBs 4EL1 and 4EKZ) were prepared (VEGA ZZ, UCSD 
Chimera PDB2PQR) as model files suitable for virtual 
docking using AutoDock Vina (http://vina.scripps.ed). 
Both were subject to unbiased ligand-receptor docking 
in full molecular space with no restraints. The high 
probability models were selected for further analysis 
as two chain PDB models. Such data provides specific 
information on the PDI inhibitor binding with PDI.
Comparison of PIF and 16F16 binding sites on 
PDI in order to determine PIF inhibitory action
In order to assess potential binding sites, 16F16 
and PIF were superimposed using their predicted docking 
positions over PDI and Chimera as molecular visualization 
tool. PIF had only one predicted site based on the site 
predicted by PepSite 2 and refined in its binding by 
FlexPepDock, while 16F16 had several binding locations 
predicted by AutoDock Vina, depending on the PDI form 
- reduced or oxidized. 
Confirmation of 16F16 / PIF ligand-receptor 
binding to PDI
To assess the ligand-receptor binding interface 
of 16F16 to PDI and that of PIF to PDI, LigPlot plus 
algorithm was used to generate automatic schematic 
diagrams of protein-ligand interactions, based on hydrogen 
bonds and hydrophobic contacts. Hydrogen bonds are 
indicated by dashed lines between the atoms involved, 
while hydrophobic contacts are represented by an arc with 
spikes radiating towards the ligand atoms they contact. 
The contacted atoms are shown with spikes radiating back. 
LIGPLOT algorithm is described in detail in Wallace et al 
[46]. The program is suitable for both small molecules - 
protein and peptide/protein-protein interactions. 
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Statistical analysis
The effect of PIF on embryo development following 
exposure to fractionated sera was determined by using chi 
square analysis and degree of freedom where p < 0.05 was 
considered as statistically significant.
The effect of added PIF and 16F16 on the cleavage 
of zygotes, assessed at 2 days after fertilization and 
development of embryos to the blastocyst stage by day 
8 after fertilization was compared between groups by 
mixed-effects logistic regression. Main effects were PIF, 
PDI-inhibitor, and their interaction. Replicate (week of 
experiment) was included as a random variable (Stat-IC 
11.2 for Windows; StataCorp LP, College Station TX). 
Where logistic regression indicated overall differences, 
post-hoc comparisons of selected groups were made using 
Chi-square statistics (MedCalc Statistical Software version 
14.12.0, Ostend, Belgium; http://www.medcalc.org; 2014). 
p < 0.05 was regarded as significant.
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